ArticleFrontiers in microbiology2025
PCV2 Cap protein nuclear import via importin α/β receptor: molecular insights and antiviral potential.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine circovirus type 2 (PCV2) Cap protein serves as the primary structural component and plays multiple roles in viral infection. Previous studies have shown that Cap predominantly localizes to the nucleus, but the molecular mechanisms governing its nuclear import remain unclear. This study demonstrates that PCV2 Cap undergoes an active nuclear transport process dependent on Ran-GTP and importin α, but not transportin-1. Co-immunoprecipitation assays revealed interactions between Cap and several host nuclear transport receptors (NTRs), including all importin α subunits, importin 4, 5, 7, and 11. Furthermore, the small molecule inhibitor importazole (IPZ) partially inhibits the nuclear translocation of Cap and suppresses Cap expression, as well as PCV2 replication. While ivermectin (IVM) only impedes transport without affecting viral replication. These findings provide significant insights into the molecular mechanisms of PCV2-Cap nuclear import and highlight potential therapeutic targets for antiviral strategies aimed at disrupting viral capsid transport.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.